Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles.
Qizhi Hu, Cristianne J Rijcken, Ruchi Bansal, Wim E Hennink, Gert Storm, Jai Prakash
Index: Biomaterials 53 , 370-8, (2015)
Full Text: HTML
Abstract
Treatment with chemotherapy such as docetaxel (DTX) is associated with significant toxicity and tumour recurrence. In this study, we developed DTX-entrapped core-cross-linked polymeric micelles (DTX-CCL-PMs, 66 nm size) by covalently conjugating DTX to CCL-PMs via a hydrolysable ester bond. The covalent conjugation allowed for sustained release of DTX under physiological conditions in vitro. In vivo, DTX-CCL-PMs demonstrated superior therapeutic efficacy in mice bearing MDA-MB-231 tumour xenografts as compared to the marketed formulation of DTX (Taxotere(®)). Strikingly, a single intravenous injection of DTX-CCL-PMs enabled complete regression of both small (∼150 mm(3)) and established (∼550 mm(3)) tumours, leading to 100% survival of the animals. These remarkable antitumour effects of DTX-CCL-PMs are attributed to its enhanced tumour accumulation and anti-stromal activity. Furthermore, DTX-CCL-PMs exhibited superior tolerability in healthy rats as compared to Taxotere. These preclinical data strongly support clinical translation of this novel nanomedicinal product for the treatment of cancer. Copyright © 2015 Elsevier Ltd. All rights reserved.
Related Compounds
Related Articles:
2015-03-15
[Cancer Res. 75(6) , 1102-12, (2015)]
2015-04-13
[Biomacromolecules 16(4) , 1382-9, (2015)]
2015-04-22
[J. Ethnopharmacol. 164 , 265-72, (2015)]
2015-01-01
[Bioresour. Technol. 176 , 156-62, (2014)]
2014-12-08
[Biomacromolecules 15(12) , 4561-9, (2014)]